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Abstract
Selective elimination of metastatic stem cells (MetSCs) promises to
block metastatic dissemination. Colorectal cancer (CRC) cells over-
expressing CXCR4 display trafficking functions and metastasis-
initiating capacity. We assessed the antimetastatic activity of a
nanoconjugate (T22-GFP-H6-FdU) that selectively delivers Flox-
uridine to CXCR4+ cells. In contrast to free oligo-FdU, intravenous
T22-GFP-H6-FdU selectively accumulates and internalizes in
CXCR4+ cancer cells, triggering DNA damage and apoptosis, which
leads to their selective elimination and to reduced tumor re-initia-
tion capacity. Repeated T22-GFP-H6-FdU administration in cell line
and patient-derived CRC models blocks intravasation and comple-
tely prevents metastases development in 38–83% of mice, while
showing CXCR4 expression-dependent and site-dependent reduc-
tion in foci number and size in liver, peritoneal, or lung metastases
in the rest of mice, compared to free oligo-FdU. T22-GFP-H6-FdU
induces also higher regression of established metastases than free
oligo-FdU, with negligible distribution or toxicity in normal tissues.
This targeted drug delivery approach yields potent antimetastatic
effect, through selective depletion of metastatic CXCR4+ cancer
cells, and validates metastatic stem cells (MetSCs) as targets for
clinical therapy.
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Introduction
Control of metastatic spread remains an unmet medical need. In
colorectal cancer (CRC), as in other tumor types, adjuvant therapy
controls metastases and prolongs survival at the expense of high
toxicity; however, metastases remain the primary cause of death
(Schrag, 2004; Mehlen & Puisieux, 2006; Spano et al, 2012; Riihima¨ki
et al, 2016). There is an urgent need to develop less toxic and more
effective antimetastatic agents. To achieve this goal, preclinical
and clinical drug development should shift its focus from primary
tumor to metastasis control, using metastatic cancer models and
evaluating promising drugs in patients with limited or non-meta-
static disease (Steeg & Theodorescu, 2008; Steeg, 2016). This is
relevant because metastases differ from primary tumors in their
mutational or gene expression profiles (Rhodes & Chinnaiyan,
2005; Vignot et al, 2015) and response to drugs (Takebayashi et al,
2013; Chen et al, 2015).
Metastatic stem cells (MetSCs) are a subset of cancer stem cells
(CSCs) that, in addition to self-renewal and differentiation capaci-
ties, have trafficking functions (Steeg, 2016; Brabletz et al, 2005;
Sleeman & Steeg, 2010; Oskarsson et al, 2014). In CRC, CXCR4
receptor enhances metastatic dissemination and confers poor patient
prognosis (Kim et al, 2005, 2006; Schimanski et al, 2005), a finding
similar to other cancers (Mu¨ller et al, 2001; Balkwill, 2004; Kucia
et al, 2005; Schimanski et al, 2006; Hermann et al, 2007; Sun et al,
2010). Moreover, CXCR4-overexpressing (CXCR4+) cells have
metastasis-initiating capacity (MICs) in CRC (Croker & Allan, 2008;
Zhang et al, 2012), whereas CXCR4 RNAi-mediated downregulation
or blockade of membrane localization inhibits hepatic and lung
metastases (Murakami et al, 2013; Wang et al, 2014). These
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findings support a MetSC function for CXCR4+ CRC cells. Neverthe-
less, the formal proof for MetSCs clinical relevance will only come
by demonstrating that their selective targeting and elimination leads
to antimetastatic effect.
Nanomedicine pursues targeted drug delivery, which aims at
increasing anticancer effect while reducing toxicity (Das et al, 2009).
We here use targeted drug delivery to CXCR4+ MetSCs in an attempt
to achieve their selective elimination. We produced the drug
nanoconjugate T22-GFP-H6-FdU by covalently binding a protein
nanoparticle, which selectively targets CXCR4+ cancer cells (Unzueta
et al, 2012a; Ce´spedes et al, 2016) to Floxuridine (FdU), a cytotoxic
drug used to treat CRC liver metastases (Shi et al, 2015). We here
demonstrate selective T22-GFP-H6-FdU biodistribution to tumor and
metastatic foci in cell line- and patient-derived CRC models. We also
observed its internalization and selective FdU delivery in CXCR4+
MetSCs, leading to their depletion. After repeated T22-GFP-H6-FdU
administration, and in contrast to free oligo-FdU, we achieved highly
significant activity in the prevention and regression of metastases in
the absence of toxicity, supporting the clinical relevance of develop-
ing drugs that selectively target MetSCs to achieve metastasis control.
Results
Development of T22-GFP-H6-FdU, a nanoconjugate that targets
CXCR4+ CRC cells
The previous demonstration of MIC capacity for CXCR4-overexpres-
sing (CXCR4+) CRC cells (Croker & Allan, 2008; Zhang et al, 2012),
and its inhibition by CXCR4 downregulation (Murakami et al, 2013;
Wang et al, 2014), identifies these cells as MetSCs (Oskarsson et al,
2014). On this basis, we generated a CXCR4-targeted nanoconjugate
to evaluate its capacity to achieve antimetastatic effect by selectively
eliminating CXCR4+ CRC cells. The structure and physico-chemical
characterization of this new T22-GFP-H6-FdU nanoconjugate are
described in Fig 1A–C, and Appendix Figs S1 and S2, which contains
T22 (a ligand that targets the CXCR4 receptor), a green fluorescent
protein (allowing its in vivo monitoring) and oligo-FdU, an oligonu-
cleotide of a drug active against CRC (Shi et al, 2015), which allows
to load a high number of drug molecules into the nanoconjugate.
T22-GFP-H6-FdU was synthesized by functionalizing oligo-FdU
with thiol (Fig 1C and Appendix Fig S1A), which was subsequently
conjugated to the previously described T22-GFP-H6 protein
nanoparticle (Unzueta et al, 2012a) once bound to a chemical linker
(Fig 1C).
We physico-chemically characterized the HS-oligo-FdU. The
functionalized pentamer FdU-HEG-SH was quantified by absorption
at 260 nm and confirmed by MALDI mass spectrometry (MALDI-
TOF), yielding a MW of 1,976.2, being the expected MW 1,974.0.
The control pentanucleotide (free oligo-FdU) characterized by mass
spectrometry (MALDI-TOF) yield a MW of 1,476.5, being the
expected MW: 1,478.1. The analysis of the conjugation products
was performed by MALDI-TOF spectra identifying the peaks corre-
sponding to one or two molecules of pentaoligonucleotides of FdU
bound to the nanoparticle with the MW indicated in Appendix Figs
S1 and S2. The T22-GFP-H6-FdU size was determined by dynamic
light scattering, being 14.6 + 0.14, as compared to 13.4 + 0.11 for
the control T22-GFP-H6 nanoparticle, a size consistent with that
determined by transmission electron microscopy.
This product had an approximate FdU/nanoparticle (DNR) ratio
of 20 (Appendix Fig S2), and maintained its capacity for self-assem-
bling (Unzueta et al, 2012a; Rueda et al, 2015; Appendix Fig S2D).
The determined size was higher than the renal filtration cutoff (6–
7 nm) ensuring a high re-circulation time in blood, a requirement
for effective targeted drug delivery (Unzueta et al, 2012b, 2015).
T22-GFP-H6-FdU selectively internalizes and kills CXCR4+ CRC
cells in vitro
Following, we used the human SW1417 CRC cell line to assess if the
loaded oligo-FdU conferred cytotoxic activity to the nanoparticle
while maintaining its CXCR4 targeting capacity, provided that drug
conjugation can alter protein conformation and function (Goswami
et al, 2013). We first determined that this cell line constitutively
▸Figure 1. T22-GFP-H6-FdU nanoconjugate synthesis and selective internalization and killing of CXCR4+ CRC cells in vitro.A The nanoconjugate contains a fusion protein [T22-GFP-H6—composed of the peptide T22 as a CXCR4 ligand, a green fluorescent protein and a histidine tail—bound
to the payload drug (Unzueta et al, 2012a)].
B Three to four pentameric oligonucleotides (approximately 20 molecules) of the antitumor drug 5-Fluoro-20-deoxyuridine (FdU), named oligo-FdU, are conjugated to
the T22-GFP-H6 targeting vector using a linker.
C T22-GFP-H6-FdU chemical synthesis: T22-GFP-H6 is first covalently bound to the 6-Maleimidohexanoic acid N-hydroxysuccinimide ester linker through its amino
groups in the external lysines (Hermanson, 2013). The thiol-functionalized oligo-FdU (oligo-(FdU)5-SH; see Appendix Fig S1) is then reacted with T22-GFP-H6
functionalized with maleimide (Michael reaction).
D High and constitutive expression of CXCR4 in the membrane of SW1417 CRC cells as measured by flow cytometry.
E Lack of human SDF-1a release from cultured SW1417 CRC cells, as measured by ELISA, whereas human control 1BR3.G fibroblasts express high SDF-1a levels, after 48
or 72 h of growth in culture (mean  s.e.m., N = 2 experiment in duplicate).
F Nanoconjugate internalization in CXCR4-overexpressing (CXCR4+) SW1417 CRC cells after 1-h exposure at 1 lM, as measured by fluorescence emission using flow
cytometry (mean  s.e.m., N = 3 experiments in duplicate). Significant difference at **P = 0.002 between the T22-GFP-H6-FdU and the T22-GFP-H6-FdU + AMD3100
groups, Mann–Whitney U-test.
G Intracellular trafficking of T22-GFP-H6-FdU in CXCR4+ SW1417 cells by confocal microscopy after exposure at 1 lM for 24 h. The green staining corresponds to GFP-
containing nanoconjugates, and the red staining corresponds to plasma cell membranes stained with a red dye (CellMaskTM), whereas cell nucleus was stained in blue
with Hoechst. The insets show detail of the intracellular localization of nanostructured, fluorescent entities, in an isosurface representation within a three-
dimensional volumetric x-y-z data field.
H Linearized T22-GFP-H6-FdU dose–response trend line representation compared with unconjugated free oligo-FdU exposure. Antitumor effect was measured as
CXCR4+ SW1417 cell viability by MTT after 72-h exposure as the described concentrations (mean  s.e.m., N = 3 experiments in duplicate).
I Reduction in cell viability determined by optical microscope images of SW1417 cells exposed to 1 lM T22-GFP-H6-FdU for 72 h, as compared to T22-GFP-H6 or free
oligo-FdU (N = 3 experiments in duplicate; Scale bar, 100 lm).
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expresses membrane CXCR4 (Fig 1D) while lacking SDF-1a expres-
sion (Fig 1E). Then, we demonstrated T22-GFP-H6-FdU capacity to
internalize in CXCR4+ SW1417, as measured by fluorescence emis-
sion using flow cytometry (Fig 1F), and to accumulate and traffic
into its cytosol as observed by confocal microscopy (Fig 1G). The
nanoconjugate maintains also its dependence on CXCR4 for inter-
nalization, since AMD3100, a CXCR4 antagonist, was able to
downregulate CXCR4 receptor in the membrane and completely
blocked nanoconjugate internalization (Fig 1F). In addition, T22-
GFP-H6-FdU induced significantly higher cytotoxicity than free
oligo-FdU in the same cells, as measured by cell viability (Fig 1H)
or phase-contrast microscopy (Fig 1I). We confirmed CXCR4-
dependent nanoconjugate internalization and higher cytotoxicity
than free oligo-FdU in human CXCR4+ HeLa cells (Appendix Fig
S3A–D).
T22-GFP-H6-FdU selectively targets CXCR4+ CRC cells in vivo
Once CXCR4-dependence for T22-GFP-H6-FdU in vitro activity was
established, we investigated whether the nanoconjugate could
achieve targeted drug delivery after its intravenous administration
in the subcutaneous (SC) CXCR4+ SW1417 CRC model. We assayed
its selectivity and CXCR4 dependence regarding tumor tissue
uptake, internalization in CXCR4-overexpressing MetSCs (target
cells), intracellular release of the cytotoxic drug FdU, and selective
CXCR4+ MetSC killing (Fig 2A).
T22-GFP-H6-FdU showed selective tumor uptake, as measured
by fluorescence emission, 5 h after the injection of a 100 lg dose
in mice (Fig 2B) as previously demonstrated for T22-GFP-H6
(Ce´spedes et al, 2016). Moreover, T22-GFP-H6-FdU selectively
internalized into CXCR4+ tumor cells as determined by their co-
localization (merged yellow color) in the cell membrane, using
dual anti-GFP and anti-CXCR4 immunofluorescence, as well as the
detection of released nanoconjugate into the CXCR4+ cell cytosol
(green dots; Fig 2C). In addition, administering the CXCR4 antago-
nist AMD3100 to mice prior to the nanoconjugate completely
blocked its tumor uptake (Fig 2D) as well as its internalization in
CXCR4+ cancer cells (Fig 2E and F). Therefore, the nanoconjugate
achieves not only selective tumor biodistribution, but also its
specific internalization into target CXCR4+ cancer cells, in a
CXCR4-dependent manner.
T22-GFP-H6-FdU achieves targeted drug delivery leading to
selective depletion of CXCR4+ cancer cells in CRC tumors
We next used the same SC SW1417 CRC model to assess if the selec-
tive internalization into the cytosol of CXCR4+ target cancer cells
achieved by the nanoconjugate led to selective FdU delivery. We
also evaluated whether the delivered FdU could induce DNA
damage and caspase-3-dependent cell death, triggering the specific
elimination of CXCR4+ tumor cells. To that aim, we used c-H2AX
IHC to measure the generation of DNA double-strand breaks (DSBs),
since they mediate FdU antitumor activity (Longley et al, 2003).
Five hours after T22-GFP-H6-FdU treatment, the number of cells
containing DSBs foci in tumors (22.8  1.4) was significantly higher
(P = 0.02) than after free oligo-FdU treatment (13.4  0.7), whereas
cells containing DSBs in control T22-GFP-H6 or Buffer-treated
tumors were barely detectable (Fig 3A and B).
T22-GFP-H6-FdU induction of DSBs indicated its capacity to
release FdU in target cells to reach the nucleus and incorporate into
DNA to induce DNA damage. In addition, the number of cleaved
caspase-3-positive cells signaling for apoptosis (IHC measured using
anticleaved caspase-3 antibody) 5 h after T22-GFP-H6-FdU treat-
ment (10.1  1.0) was significantly higher (P = 0.03) than after free
oligo-FdU (5.2  0.9) treatment (Fig 3A and B). Moreover,
increased DSB-positive cells led to higher antitumor activity, since
the number of cell dead bodies, measured by Hoechst staining,
which identify nuclear condensation or defragmentation, in tumor
tissue 24 h after T22-GFP-H6-FdU injection was significantly
(P = 0.03) higher (13.9  0.5) than free oligo-FdU (7.1  0.6), T22-
GFP-H6 (3.0  0.3), or Buffer (1.9  0.4) treatment (Fig 3A and B).
Following, we analyzed the fraction of CXCR4+ cancer cells
(CXCR4+ CCF) remaining in tumor tissue, along time, after a single
100 lg T22-GFP-H6-FdU dose, as compared to free oligo-FdU, using
the SC CXCR4+ SW1417 CRC model in NOD/SCID mice. Before
treatment, both groups showed a similar CXCR4+ CCF in tumor
tissue (Fig 4A and B); however, after T22-GFP-H6-FdU treatment,
the CXCR4+ CCF was reduced at 24 h and reached its valley at 48 h
▸Figure 2. Selective biodistribution and receptor-dependent uptake of T22-GFP-H6-FdU in CXCR4+ cells in vivo.A Approach to achieve targeted drug delivery and selective killing of metastatic stem cells: CXCR4-nanoconjugate interaction triggers CXCR4-mediated internalization
in MetSCs, in primary tumors and metastatic foci, followed by FdU release to the cytosol and diffusion to the nucleus to induce double-strand breaks leading to
selective killing of CXCR4+ cells.
B Selective T22-GFP-H6-FdU nanoconjugate biodistribution in subcutaneous CXCR4+ SW1417 CRC tumor tissue 5 h after a 100 lg single intravenous dose, as
measured by fluorescence emission using IVIS Spectrum 200 (N = 5/group). Biodistribution is similar to that achieved by the T22-GFP-H6 targeting vector and
undetectable after Buffer or free oligo-FdU treatment (N = 5 mice/group).
C Co-localization (yellow merged) of the T22-GFP-H6-FdU (green) and the CXCR4 receptor (red) and release of T22-GFP-H6-FdU into the cytosol in CXCR4+ tumor cells
5 h after a 100 lg dose of nanoconjugate, as measured by dual anti-GFP/anti-CXCR4 immunofluorescence (IF). DAPI (blue nuclear staining). Fluorescence emission
was measured in the green and red channels using the ImageJ software and expressed as mean area (A)  s.e.m (lm2) (N = 10, 2 tumor fields × 5 mice; 200×). Note
the significant (P = 0.003) increase in the area occupied by the green dots (nanoconjugate released to the cell cytosol) in T22-GFP-H6-FdU-treated tumors, compared
to free oligo-FdU-treated control tissues. Scale bar, 50 lm.
D Administration of the CXCR4 antagonist AMD3100 completely blocks T22-GFP-H6-FdU tumor biodistribution, as measured by fluorescence emission. Fluorescence is
not detected in Buffer or free oligo-FdU controls (N = 5 tumor fields/group).
E The uptake of T22-GFP-H6-FdU observed in CXCR4+ SW1417 tumor tissues is almost completely blocked by prior AMD3100 administration, as quantified using the
anti-GFP IHC H-score (mean  s.e.m., N = 5 tumor fields/group). Comparison of T22-GFP-H6 uptake between groups: (B: Buffer; F: free oligo-FdU; T-F: T22-GFP-H6-FdU;
T-F+A: T22-GFP-H6-FdU+AMD3100). P-values for statistical differences B vs. T-F, **P = 0.000; F vs. T-F, **P = 0.000; T-F vs. TFA, **P = 0.004. Mann–Whitney U-test.
F Representative images of T22-GFP-H6-FdU uptake and AMD3100 competition by anti-GFP immunostaining, which quantitation is reported in panel (E). Scale bar,
50 lm.
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(Fig 4A and B). In contrast, the CXCR4+ CCF in tumor tissue after
an equimolecular dose of free oligo-FdU remained similar to its
basal level along time. Taken together, these results indicate that
T22-GFP-H6-FdU achieves selective biodistribution to tumor tissue
and FdU delivery to target CXCR4+ cancer cells, as indicated by an
enhancement in DNA damage and apoptotic tumor cell death, which
triggers selective elimination of CXCR4+ cancer cells in vivo, achiev-
ing, therefore, targeted FdU delivery to target cancer cells.
Transient target cell elimination and definition of a dose interval
for repeated T22-GFP-H6-FdU injection
Despite T22-GFP-H6-FdU achieved selective depletion of CXCR4+
target cells in tumor tissue observed 48 h after its administration, we
found this effect to be transient, since 72 h post-injection CXCR4+
cancer cell fraction in tumor tissue grew back, nevertheless, to reach
a level lower than that basal before therapy (Fig 4A and B). In
contrast, the CXCR4+ CCF in tumor tissue after free oligo-FdU ther-
apy was maintained over time, remaining similar at 24, 48, or 72 h
after treatment as before therapy (Fig 4A and B). Therefore, in
contrast to T22-GFP-H6-FdU effect, cancer killing by free oligo-FdU
did not show selectivity toward CXCR4+ cancer cells. Based on these
results, and in order to evaluate T22-GFP-H6-FdU antimetastatic
effect, we defined a 72 h (3 days) dose interval as optimal for its
administration in a repeated dose schedule. We expected this regime
to maintain sufficiently low the fraction of CXCR4+ cancer cells
remaining in primary tumors and metastatic foci, along the treatment
period, as to efficiently block metastasis and/or foci growth, provided
that CXCR4+ cancer cells act as MetSCs.
T22-GFP-H6-FdU-treated tumors reduce their spheroid formation
and tumor re-initiation capacities
We next used the CXCR4+ luciferase+ SW1417 SC CRC model to
assess if the selective CXCR4+ cancer cell killing induced by T22-
GFP-H6-FdU treatment in vivo was capable of blocking spheroid
formation in vitro. Thus, we cultured 1 × 106 disaggregated cells in
stem cell- conditioned media and low-adhesion plates that were
obtained from CXCR4+ luciferase+ SW1417 subcutaneous tumors,
24 h after 100 lg T22-GFP-H6-FdU i.v. doses, for 2 consecutive
days, and observed a reduction in spheroid formation (Fig 4C), as
compared to cells obtained after an equimolar free-FdU or Buffer
treatment. The bioluminescence intensity emitted by the spheroids
generated after T22-GFP-H6-FdU treatment (9.1 × 107  3.2 × 107)
was significantly (P = 0.02) reduced as compared to free oligo-FdU
(19.0 × 107  0.38 × 107) or Buffer (40.0 × 107  1.9 × 107) treat-
ment (Fig 4D). Similarly, culture of 1 × 106 disaggregated cells
obtained from patient-derived CXCR4+ M5 subcutaneous tumors,
treated with the same T22-GFP-H6-FdU dosage, leads to a significant
(P = 0.001) reduction in the number of formed spheroids
(19.1  1.2), as compared to free oligo-FdU-treated (46.3  3.1) or
Buffer-treated (73.1  7.0) mice (Fig 5A and B).
In addition, the inoculation of 5 × 106 cells, subcutaneously in
recipient NSG mice, derived from disaggregated tumor cells
obtained from CXCR4+ M5 SC tumors after the administration of
100 lg T22-GFP-H6-FdU intravenous doses, for 2 consecutive days,
leads to a reduction in tumor re-initiation (as measured as dimin-
ished number and size of tumors) 10 days after the end of treat-
ment, as compared to free oligo-FdU-treated or Buffer-treated mice
(Fig 5C and D). Thus, in both, the SW1417 and the M5 CRC models
CXCR4+ cancer cells behave as cancer stem cells since their selec-
tive elimination reduces their tumor re-initiation capacity.
T22-GFP-H6-FdU-induced blockade of tumor emboli intravasation
Following, we assessed if T22-GFP-H6-FdU treatment of patient-
derived CXCR4+ M5 orthotopic tumors blocked dissemination from
the primary tumors at an early time. To this aim, 7 days after implan-
tation of two million M5 tumor cells in the mouse cecum, we admin-
istered 100 lg T22-GFP-H6-FdU intravenous doses, for 2 consecutive
days, and 24 h later sacrificed the mice and proceed to H&E staining
of samples from tumors and peri-tumoral areas. We observed that
T22-GFP-H6-FdU administration induced a significant (P = 0.016)
reduction in the number of intravasated tumor emboli within the
vessels of the peri-tumoral area (1.6  0.4), which were microscopi-
cally detected, in comparison with free oligo-FdU-treated (5.4  1.3)
or Buffer-treated (5.1  2.0) tumors (Fig 5E and F). Moreover, T22-
GFP-H6-FdU treatment reduced also significantly (P = 0.027) the H-
score (percent and intensity of IHC stained and normalized by foci
area) for CXCR4 expression in peri-tumoral intravasated tumor
emboli (0.017  0.012), as compared to free oligo-FdU-treated
(0.043  0.010) or Buffer-treated (0.038  0.005) tumors (Fig 5E–
G). Thus, T22-GFP-H6-FdU blocks tumor emboli intravasation in the
primary tumor peri-tumoral vessels.
T22-GFP-H6-FdU induces the regression of
established metastases
We assessed T22-GFP-H6-FdU capacity to inhibit growth of estab-
lished metastases, as compared to equimolecular doses of T22-GFP-
◀ Figure 3. T22-GFP-H6-FdU-induced depletion of CXCR4-overexpressing cancer cells in tumor tissue.A Representative images of CXCR4 overexpression in subcutaneous tumor tissue, showing similar CXCR4 levels among compared groups (N = 5/group; Buffer, T22-GFP-
H6-FdU, T22-GFP-H6, and free oligo-FdU) before treatment (upper panels). Representative images of DNA double-strand break induction and caspase-3 activation
(measured with anti-c-H2AX or anticleaved caspase-3 by IHC) 5 h post-administration (middle panels). Apoptotic induction (Hoechst staining, 24 h post-
administration, lower panels). Note the higher number of cells positive for DSBs, caspase-3 activation, and apoptosis induction in the T22-GFP-H6-FdU as compared
to free oligo-FdU. Black or white arrows indicate dead cells. Scale bar, 50 lm.
B Quantitation of the number of cells containing DSBs or active caspase-3 in IHC-stained tumor sections 5 h post-treatment and the number of condensated or
disaggregated nuclei (by Hoechst staining) 24 h post-treatment in tumor sections of 10 high-power fields (400× magnification) using the Cell^D software (N = 50; 10
tumor fields/mice; 5 mice/group). Data expressed as mean  s.e.m. Parameter comparison between groups: (B: Buffer; T: T22-GFP-H6; F: free oligo-FdU; T-F: T22-GFP-
H6-FdU). P-values for statistical differences: c-H2AX staining quantitation: B vs. T, #P = 0.001; B vs. F, #P = 0.000; B vs. T-F, #P = 0.000; T vs. T-F, **P = 0.001; F vs.
T-F, *P = 0.02. Cleaved caspase-3 quantitation: B vs. F, *P = 0.034; B vs. T-F, **P = 0.009; T vs. T-F, **P = 0.003; F vs. T-F, *P = 0.012. Hoechst staining quantitation:
B vs. F, **P = 0.01; B vs. T-F, **P = 0.001; T vs. T-F, **P = 0.000; F vs. T-F, *P = 0.032. Mann Whitney U-test.
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H6 or free oligo-FdU, using an orthotopic bioluminescent CXCR4+
CRC model in Swiss nude mice, which generates lymph node (LN)
and lung (LG) metastases (Mets), starting therapy 2 months after
CRC cell implantation, given a 20 lg i.v. q3d dosage (Appendix Fig
S5A). At the end of the regression of metastasis experiment, T22-
GFP-H6-FdU-treated mice registered a lower number of LG Mets
than free oligo-FdU, as measured by ex vivo bioluminescence emis-
sion (Appendix Fig S6A). This was confirmed by the finding of 3.0-
and 2.9-fold reduction in total and mean LG foci number in histol-
ogy sections of the T22-GFP-H6-FdU group as compared to free
oligo-FdU (P = 0.04) mice (Appendix Fig S6B and C). T22-GFP-H6-
FdU mice had a significantly lower number of LN Mets than Buffer-
treated mice (P = 0.03); however, its effect was similar to that
achieved by free oligo-FdU treatment.
T22-GFP-H6-FdU prevents hematogenous and transcelomic
metastases in the SW1417 cell line-derived CRC model
We also evaluated T22-GFP-H6-FdU capacity to prevent metastasis
as compared to free oligo-FdU, by registering the percent of mice
with undetectable metastases at the end of treatment (Mets-free
mice) and the reduction in number and size of Mets foci in mice
with detectable metastases (Mets+ mice) at the end of the experi-
ment, using the CXCR4+ SW1417 orthotopic bioluminescent CRC
model, which metastasizes to lymph nodes (LN), liver (LV), lung
(LG), and peritoneum (PTN), starting treatment 1 week after CRC
implantation and following a schedule of 20 lg, q3d, 12 doses
(Appendix Fig S5B).
At the end of the experiment, and in contrast to findings in Buffer
or oligo-FdU groups, T22-GFP-H6-FdU treatment potently prevented
hematogenous (LV and LG) and transcelomic (PTN) Mets develop-
ment, whereas its capacity to prevent LN Mets was low. Thus, the
percent of LV, LG, and PTN Mets-free mice after Buffer treatment
was 45–55 and 27–64% for oligo-FdU, whereas T22-GFP-H6-FdU
treatment increased significantly (P = 0.004) to reach 83% of Mets-
free mice at all sites (Table 1 and Appendix Table S1). The dif-
ferences in Mets-free mice between Buffer and oligo-FdU mice were
not significant.
Consistently, in Mets+ mice, T22-GFP-H6-FdU reduced the LV
and LG Mets number, as measured by ex vivo bioluminescence
compared to free oligo-FdU effect (data not shown). Moreover, a
histological analysis of the foci number and size in LV, LG, and PTN
Mets+ mice at the end of treatment showed that T22-GFP-H6-FdU
mice had a 7.3- and 7.0-fold reduction in the total and mean PTN
foci number (P = 0.0001), and a 2.4-fold reduction in PTN foci size
(P = 0.01) as compared to free oligo-FdU (Appendix Fig S8A and
Table 1). Similarly, T22-GFP-H6-FdU induced a 2.7- and 5.0-fold
reduction in total and mean number of LV (P = 0.001) or LG (4.5-
and 3.5-fold, P = 0.006) Mets as compared to free oligo-FdU, and
only a mild effect on LN Mets. Importantly, free oligo-FdU did not
reduce the total or mean Mets foci number at any site (LN, LV, LG,
PTN), as compared to Buffer-treated animals (Appendix Fig S8A and
Table 1).
T22-GFP-H6-FdU prevents hematogenous and transcelomic
metastases in the M5 patient-derived CRC model
We, next assessed T22-GFP-H6-FdU capacity to prevent LN, LV, LG,
and PTN Mets development in the CXCR4+ M5 orthotopic CRC
model, which shows higher metastatic efficiency at all sites (Table 1).
To that aim, we measured all parameters described above in the
SW1417 model and applied a schedule of 20 lg, q3d, per seven
doses, starting 1 week after tumor cell implantation (Appendix Fig
S5C). T22-GFP-H6-FdU treatment potently prevented LV, LG, and
PTN Mets development, whereas its capacity to prevent LN Mets was
low (Table 1). Thus, the percent of LV, LG, and PTN Mets-free mice
was 0% after Buffer treatment and 15–30% after free oligo-FdU treat-
ment, whereas T22-GFP-H6-FdU treatment significantly (P = 0.05)
increased this effect to reach 38–63% of LV, LG, and PTN Mets-free
mice. The differences between Buffer and oligo-FdU treatment were
not significant (Table 1 and Appendix Table S1).
The histological evaluation of LV, LG, and PTN foci in Mets+
mice at the end of treatment showed that T22-GFP-H6-FdU mice
registered a 9.0- and 9.4-fold reduction in the total and mean LV foci
number (P = 0.001), and 12.1-fold reduction in LV foci size
(P = 0.007) as compared to free oligo-FdU (Fig 6A and Table 1).
Similarly, T22-GFP-H6-FdU induced a 5.7- and 2.7-fold reduction in
total and mean number of PTN (P = 0.022) or LG (2.4- and 2.8-fold,
P = 0.003) Mets as compared to free oligo-FdU and having, and only
a mild effect on LN Mets (Fig 6A and Table 1). Importantly, in
contrast to T22-GFP-H6-FdU, free oligo-FdU did not reduce the total
or mean Mets foci number at any site (LN, LV, LG, PTN), as
compared to Buffer-treated animals (Fig 6A and Table 1).
In summary, repeated T22-GFP-H6-FdU administration potently
prevented the development of hematogenous (LV and LG) and tran-
scelomic (PTN) metastases yielding a 38–83% of Mets-free mice,
◀ Figure 4. T22-GFP-H6-FdU-induced depletion of CXCR4-overexpressing cancer cells in tumor tissue leading to reduced spheroid formation capacity.A, B T22-GFP-H6-FdU depletes CXCR4+ cancer cells from SW1417 CRC tumor tissue after a 100 lg single-dose administration. Note the reduction in CXCR4+ cell
fraction in the tumor 24 h after injection, their almost complete elimination at 48 h, and the re-emergence of CXCR4+ cells 72 h post-administration, using anti-
CXCR4 IHC. In contrast, the CXCR4+ cancer cell fraction (CXCR4+ CCF) in tumor tissue remains constant along time after free oligo-FdU treatment. The 3-day time-
lapse for CXCR4+ tumor cell re-appearance defines the dosage interval used in a repeated dose schedule of nanoconjugate administration in the experiments to
evaluate its antimetastatic effect (N = 5: 5 mice/group; 1 samples/mouse). Scale bar, 50 lm. Data expressed as mean  s.e.m. CXCR4 H-score comparison for T22-
GFP-H6-FdU(T-F)-treated tumors among time points (green line, panel A). P-values for statistical differences: T-F Basal vs. T-F 24 h, *P = 0.038; T-F Basal vs. T-F
48 h, **P = 0.001; T-F Basal vs. T-F 72 h, **P = 0.003; T-F 24 h vs. T-F 48 h, *P = 0.033. CXCR4 H-score comparison between T22-GFP-H6-FdU (T-F) and free
oligo-FdU (F) (black line, panel A). P-values for statistical differences: T-F vs. F at 48 h, **P = 0.001; T-F vs. F at 72 h, *P = 0.034). Mann–Whitney U-test.
C, D Significant reduction in the number of spheroid formed (C, optical microscope) and their bioluminescence emission (D, IVIS Spectrum 200), generated by 1 × 106
disaggregated cells (cultured in stem cell-conditioned media and low-adhesion plates), obtained from CXCR4+ luciferase+ SW1417 subcutaneous tumors, 24 h after
100 lg T22-GFP-H6-FdU intravenous doses, for 2 consecutive days, as compared to Buffer-treated or free oligo-FdU-treated mice. (D) Quantitation of the
bioluminescent signal (BLI) expressed as average radiant intensity, obtained using the IVIS spectrum 200 equipment (N = 2 plates/group). Data expressed as
mean  s.e.m. Comparison of emitted BLI between groups: (B: Buffer; F: free oligo-FdU; T-F: T22-GFP-H6-FdU). P-values for statistical differences: T-F vs. B,
**P = 0.001 (green line, panel D); F vs. B, *P = 0.011 (red line); T-F vs. F at *P = 0.02 (black line, panel D). Mann–Whitney U-test.
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depending on the site and studied model. It also reduced signifi-
cantly the number and/or size of LV, LG, and PTN foci in Mets+
mice. Nevertheless, T22-GFP-H6-FdU was unable to block LN Mets
development. In contrast, free oligo-FdU did not prevent metastases
at any site. In addition, T22-GFP-H6-FdU was more potent than free
oligo-FdU in inducing the regression of established LG Mets. Inter-
estingly, both T22-GFP-H6-FdU and free oligo-FdU showed a similar
inhibitory effect on primary tumor growth as measured by in vivo
bioluminescence emission along time or ex vivo at the end of treat-
ment, both in the prevention or regression of metastasis experi-
ments (Appendix Figs S6A and B, and S7A–D).
Site-dependent CXCR4 regulation, T22-GFP-H6-FdU CXCR4+ cell
targeting, and antimetastatic effect
Based on the clear site-dependent antimetastatic potency achieved
by T22-GFP-H6-FdU in the prevention of metastasis experiments
(Fig 6A, Appendix Fig S8A, and Table 1), on its dependence on
CXCR4 membrane expression for cell internalization (Fig 2E) and
capacity to selectively kill CXCR4+ cancer cells (Fig 3A and B), we
investigated if CXCR4 expression after therapy correlated with the
observed antimetastatic effect at the different sites.
We observed a site-dependent reduction in CXCR4+ target cancer
cell fraction (CXCR4+ CCF) in Mets foci at the end of T22-GFP-H6-
FdU treatment, as detected by anti-CXCR4 IHC, (and as compared to
basal levels) which correlated with the antimetastatic effect at the
different sites in both SW1417 and M5 patient-derived CRC models
(Fig 6B, Appendix Fig S8B, and Table 1). The LV, LG, and PTN
Mets, highly sensitive to T22-GFP-H6-FdU treatment in terms of
increased percent of Mets-free mice and reduction in foci number
and size in Mets+ mice, reached the lowest level of CXCR4+ CCF at
the end of treatment at these sites. In contrast, in both the M5 and
SW1417 models we observed only a low and non-significant reduc-
tion in CXCR4+ CCF in the organs showing low sensitivity to T22-
GFP-H6-FdU, such as the primary tumor or LN Mets (Fig 6B and C,
and Appendix Fig S8B and C). Moreover, conversely to findings
with to T22-GFP-H6-FdU, free oligo-FdU did not reduce CXCR4+
CCF at any Mets site (Fig 6A and Appendix Fig S8A). Similarly, in
the regression of metastasis experiment, we observed a CXCR4+
CCF reduction in LG Mets and higher antimetastatic effect at this site
than in LN Mets, which showed no reduction in CXCR4+ CCF and
poor response to T22-GFP-H6-FdU therapy (Appendix Fig S6C and D
and Table 1).
Lack of T22-GFP-H6-FdU accumulation or toxicity in
normal tissues
To estimate the T22-GFP-H6-FdU therapeutic window, we analyzed
its biodistribution and induction of DNA damage and apoptosis in
non-tumor tissues. T22-GFP-H6-FdU injection led to highly selective
tumor tissue accumulation (Fig 2B) as measured by fluorescence
emission, whereas uptake in CXCR4-positive (bone marrow or
spleen) or CXCR4-negative (kidney, lung, brain, heart or liver)
normal tissues was undetectable, except for a transient accumula-
tion in the liver (Fig 7A), in the same experiment. Moreover, the
number of cells containing DSBs, detected by anti-c-H2AX IHC,
in normal bone marrow 5 h after T22-GFP-H6-FdU treatment
(6.1  1.2) was significantly lower (P = 0.047) than in free oligo-
FdU-treated mice (11.4  0.9; Fig 7B), whereas DSB-positive cells
in normal liver or kidney were similarly low in all compound-
treated groups or Buffer-treated animals. Moreover, DSBs induction
did not lead to apoptosis or histological alteration in any group,
since no histological alterations were detected in bone marrow,
liver, or kidney 24 h post-administration (Fig 7C). Therefore,
consistently with the negligible nanoconjugate distribution to
normal tissues, the lack of detectable apoptosis or histological alter-
ations in all analyzed tissues, including bone marrow or circulating
blood monocytes (Appendix Fig S9), the lack of mouse body weight
loss in the regression or prevention (Fig 7D–F) of metastases experi-
ments, and the absence of any sign of clinical toxicity indicate a
wide therapeutic index for T22-GFP-H6-FdU at a dosage that
achieves potent antimetastatic effect.
Discussion
The identification of CXCR4+ tumor cells as metastasis stem cells
(MetSCs) (Oskarsson et al, 2014) in colorectal cancer (CRC; Croker
◀ Figure 5. T22-GFP-H6-FdU-induced reduction in tumor re-initiation capacity and blockade of tumor emboli intravasation in the CXCR4+ patient-derivedM5 model.
A, B Reduction in the number of formed spheroids (white arrows, optical microscope) generated by 1 × 106 disaggregated cells (cultured in stem cell-conditioned
media and low-adhesion plates) obtained from CXCR4+ M5 subcutaneous tumors, 24 h after 100 lg T22-GFP-H6-FdU intravenous doses, for 2 consecutive days, as
compared to Buffer-treated or free oligo-FdU-treated mice (mean  s.e.m., N = 8; 2 mice/group; 4 plates/mouse). Scale bar, 100 lm. Comparison of spheroid
formation between groups: (B: Buffer; F: free oligo-FdU; T-F: T22-GFP-H6-FdU). P-values for statistical differences: T-F vs. B, **P = 0.001 (green line, Panel B); F vs. B,
*P = 0.012 (red line); T-F vs. F, **P = 0.001 (black line). Mann–Whitney U-test.
C, D Reduction in tumor re-initiation capacity after subcutaneous inoculation of 5 × 106 cells in NSG mice (N = 4 tumors/group) derived from disaggregated tumor
cells obtained from SC tumors 10 days after administration of 100 lg T22-GFP-H6-FdU intravenous doses, for 2 consecutive days, as compared to free oligo-FdU-
treated or Buffer-treated mice. Recording of the number and size of positive tumors (black arrows, N = 4; 2 mice/group, 2 injection points/mouse).
E–G (E) Representative images of tumor emboli intravasation determined by microscopic analyses of H&E-stained tumor sections (N = 5/group). (F) T22-GFP-H6-FdU-
induced reduction in the number of intravasated tumor emboli (black arrows) in peri-tumoral vessels of the M5-orthotopic primary tumor (E: optical images; F:
emboli number quantitation) and reduction in CXCR4 expression in these emboli (G), treated 7 days after tumor cell implantation with 100 lg T22-GFP-H6-FdU
intravenous doses, for 2 consecutive days, as compared to Buffer-treated or free oligo-FdU-treated mice. Tumor emboli counting in 10 high-power field at 200×
magnification in H&E-stained sections from each tumor (mean  s.e.m., N = 5/group). Comparison of tumor emboli number between groups: (B: Buffer; F: free
oligo-FdU; T-F: T22-GFP-H6-FdU). P-values for statistical differences: T-F vs. B, *P = 0.038 (green line), T-F vs. F, *P = 0.016 (black line). Scale bar, 100 lm. (G)
CXCR4 expression per tumor emboli determined by using anti-CXCR4 IHC and calculating H-score (multiplying percent of CXCR4+ cells out of total cell number in
the emboli area by their staining intensity, scoring each from 0 to 3 (where 3 is the maximal intensity) per tumor emboli area (mean  s.e.m., N = 5 mice/group).
Comparison of CXCR4 H-score between groups: (B: Buffer; T-F: T22-GFP-H6-FdU). P-values for statistical differences: T-F vs. B at *P = 0.027 (green line). Mann–
Whitney U-test.
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& Allan, 2008; Zhang et al, 2012; Murakami et al, 2013; Wang et al,
2014) allowed us to evaluate the clinical relevance of targeting CRC
MetSCs by assessing whether their selective elimination induces
antimetastatic activity. Our nanotechnology approach achieved the
goal of targeted drug delivery (Das et al, 2009) to MetSCs by taking
advantage of their membrane CXCR4 overexpression, as compared
to normal tissues (Kim et al, 2005, 2006; Schimanski et al, 2005).
The T22-GFP-H6-FdU nanoconjugate replicates the nanoparticle
capacities for self-assembling, lack of renal filtration, high re-circula-
tion in blood, and selective internalization in target CXCR4+ cells,
which we described for T22-GFP-H6 (Unzueta et al, 2012a,b, 2015;
Rueda et al, 2015; Ce´spedes et al, 2016) adding the ability to
transport and intracellularly release FdU, which induces an increase
in genotoxic damage and apoptosis, leading to selective CXCR4+
cancer cell elimination as well as to a reduction in tumor re-initia-
tion capacity.
The nanoconjugate achieved potent and site-dependent metasta-
sis prevention, since its administration generated a significantly
higher percent of Mets-free mice at the end of treatment, and a
significant reduction in metastatic foci number and size. These
effects associated with a reduction in CXCR4+ target cancer cell
fraction in tumor tissue, being both the antimetastatic effect and the
reduction in CXCR4+ CCF highly significant in LV, LG, and PTN
Mets, whereas they were non-significant in primary tumor or LN
Table 1. T22-GFP-H6-FdU antimetastatic effect, observed in the prevention of metastasis experiments in the SW1417 and M5 CRC metastatic
models, measured as percent of mice free of metastases at the end of treatment and as reduction in mean foci number and foci size in metastasis-
positive mice†.
Prevention of metastasis protocol
SW1417 cell line-derived orthotopic model
Groups
Lymph node Mets (LNm) Liver Mets (LVm) Lung Mets (LGm) Peritoneal Mets (PTNm)
% Mice
free of
LN Mets
Foci # in
Mets+ mice
% Mice
free of
LV Mets
Foci # in Mets+
mice
% Mice
free of
LG Mets
Foci # in
Mets+ mice
% Mice
free of
PTN Mets
Foci # in
Mets+ mice
Buffer 0% 3.7  0.3a 64% 0.7  0.3b 27% 6.6  1.5d 36% 2.0  0.6f
Free oligo-FdU 0% 3.1  0.4 45% 1.0  0.3c 45% 4.5  1.6e 55% 2.8  1.0g
T22-GFP-H6-FdU 25% 2.0  0.4a 83% 0.2  0.1b,c 83% 1.3  0.9d,e 83% 0.4  0.3f,g
Metastatic Foci size‡ (lm2 × 103)
Groups
Lymph node
Mets (LNm)
Liver Mets
(LVm) Lung Mets (LGm)
Peritoneal
Mets (PTNm)
Buffer 110.7  15.5o 11.2  3.4 21.2  1.3p 435.7  67.2q
Free oligo-FdU 77.0  14.2o 9.6  2.3 17.9  1.6 304.8  22.3r
T22-GFP-H6-FdU 79.3  11.1 8.7  2.6 15.1  2.2p 126.6  18.7q,r
M5 patient-derived orthotopic model
Groups
Lymph node Mets (LNm) Liver Mets (LVm) Lung Mets (LGm) Peritoneal Mets (PTNm)
% Mice
free of
LN Mets
Foci # in
Mets+ mice
% Mice
free of
LV Mets
Foci # in Mets+
mice
% Mice
free of
LG Mets
Foci # in
Mets+ mice
% Mice
free of
PTN Mets
Foci # in
Mets+ mice
Buffer 0% 50.0  18.4h 0% 10.5  2.5i 0% 19.5  7.1k 0% 40.0  11.4l,m
Free oligo-FdU 0% 39.6  14.6 15% 7.5  2.7j 30% 16.2  6.9 15% 19.7  8.4l,n
T22-GFP-H6-FdU 0% 22.7  4.1h 63% 0.8  0.5i,j 50% 5.8  2.4k 38% 7.2  1.8m,n
Metastatic Foci size‡ (lm2 × 103)
Groups Lymph node Mets (LNm) Liver Mets (LVm) Lung Mets (LGm)
Peritoneal
Mets (PTNm)
Buffer 1,749.4  434.7 20.0  6.1s 10.8  1.5 3,603.3  976.6
Free oligo-FdU 1,808.4  289.2 38.7  11.7t 7.7  0.9u 3,665.6  589.2
T22-GFP-H6-FdU 1,752.2  426.3 3.2  0.7s,t 10.2  1.4u 3,057.7  1,415.4
Mean + s.e.m. metastatic foci number per mouse counted in three randomly chosen histology sections.
Free oligo-FdU: equimolecular doses of free oligo-FdU.
†See Appendix Table S1 for detailed data on metastasis-free mice and statistical analysis.
‡Mean + s.e.m. metastatic foci area (lm2) per mouse counted in three randomly chosen histology sections.
aP = 0.04; bP = 0.01; cP = 0.001; dP = 0.002; eP = 0.006; fP = 0.002; gP = 0.006; hP = 0.006; iP = 0.001; jP = 0.001; kP = 0.003; lP = 0.015; mP = 0.001;
nP = 0.022; oP = 0.009; pP = 0.032; qP = 0.002; rP = 0.01; sP = 0.02; tP = 0.007; uP = 0.017.
12 of 22 EMBO Molecular Medicine e8772 | 2018 ª 2018 The Authors
EMBO Molecular Medicine MetSCs killing as antimetastatic therapy María Virtudes Céspedes et al
Published online: September 6, 2018 
A B
Remaining CXCR4+  Cancer Cell Fraction (CXCR4+ CCF)
M5 patient-derived model
Primary 
tumor
LVm 
LGm
PTNm
Free oligo-FdU T22-GFP-H6-FdU Buffer
Low
 sensitivity to 
T22-G
FP
-H
6-FdU
H
igh sensitivity to
T22-G
FP
-H
6-FdU
LNm 
* *
N
N
N
*
*
LNLN
LN
*
*
*
N
C
Figure 6.
ª 2018 The Authors EMBO Molecular Medicine e8772 | 2018 13 of 22
María Virtudes Céspedes et al MetSCs killing as antimetastatic therapy EMBO Molecular Medicine
Published online: September 6, 2018 
Mets. Thus, the repeated dose administration at the CXCR4 expres-
sion peak in tumors (q3d) achieved our goal of maintaining the
CXCR4+ CCF absent, or low, leading to a complete elimination of
Mets (achieving, therefore, a complete elimination of CXCR4+
cancer cells) in a portion of mice, in both cell line and patient-
derived CCR models. Based on our previous findings of high T22-
GFP-H6 nanoparticle internalization in high CXCR4-expressing PTN
Mets and low internalization in low CXCR4-expressing LN Mets in
CRC mouse models (Ce´spedes et al, 2016), our results suggest that
the high T22-GFP-H6-FdU antimetastatic effect observed in peri-
toneal metastases may come from its high internalization in these
foci, leading to high intracellular FdU concentration and DNA
damage above DNA repair capacity, triggering in turn high cell
killing and a reduction in foci number as well as in CXCR4+ CCF at
the end of treatment. This is opposite to the observation of a low
internalization of the nanoconjugate and lack of antimetastatic effect
and no reduction in CXCR4+ CCF in primary tumor or LN Mets.
These findings are reminiscent of the association between antitumor
effect by inhibition of Bmi-1 self-renewal protein and reduction in
the Bmi1+ CSCs fraction (Kreso et al, 2014), and identify the
CXCR4+ CCF in cancer tissue as a possible marker for monitoring
metastasis response to T22-GFP-H6-FdU therapy.
In sharp contrast, an equimolecular dosage of unconjugated
FdU did not prevent metastases nor reduced the CXCR4+ CCF in
metastatic tissue, which may relate to its unselective biodistribu-
tion, reaching low FdU concentration in MetSCs and triggering an
insufficient level of DNA damage or apoptosis. Despite T22-GFP-
H6-FdU also induced a higher level of regression of established LG
Mets than free oligo-FdU and a similar effect on LN Mets, our
results suggest that T22-GFP-H6-FdU may be more effective at
blocking metastasis early, while disseminating from the primary
tumor or during secondary organ colonization, than at inhibiting
metastatic growth. The significant reduction in tumor emboli
intravasation in peri-tumoral vessels observed in T22-GFP-H6-FdU-
treated tumors supports this argument. This is also consistent with
the functions described for CXCR4 during early metastatic dissemi-
nation, including tumor cell trafficking at the invasion front,
intravasation, extravasation, or organ colonization in CRC, as
described in other tumor types (Zeelenberg et al, 2003; Gassmann
et al, 2009; Hernandez et al, 2011; Jin et al, 2012a,b; Wendel et al,
◀ Figure 6. T22-GFP-H6-FdU prevents metastasis in the M5 patient-derived model in a CXCR4-dependent manner.A T22-GFP-H6-FdU prevents metastases in the CXCR4+ patient-derived M5 model by potently reducing the total and mean number of liver, lung, and peritoneal Mets,
as recorded in H&E-stained histology sections at the end of treatment, in comparison with free oligo-FdU or Buffer treatment. In contrast, the number of LN Mets is
not reduced after T22-GFP-H6-FdU or free oligo-FdU administration (N = 6 mice per Buffer group; N = 7 mice per free oligo-FdU group; and N = 8 mice per T22-GFP-
H6-FdU group; 3 samples/mouse). Data expressed as mean  s.e.m. Comparison of metastatic foci number by site between groups: (B: Buffer; F: free oligo-FdU; T-F:
T22-GFP-H6-FdU). P-values for statistical differences: T-F vs. B: *P = 0.006 for LN Mets; *P = 0.001 for LV Mets; *P = 0.003 for LG Mets; *P = 0.001 for PTN Mets
(green lines), F vs. B: *P = 0.015 for PTN Mets (red line), T-F vs. F: *P = 0.001 for LV Mets, *P = 0.022 for PTN Mets (black line). Mann–Whitney U-test. See Table 1 for
the recording of the percent of metastasis-free mice (mice with undetectable metastases at the end of treatment, and therefore with an absence of CXCR4+ tumor
cells) after T22-GFP-H6-FdU treatment. Also, Table 1 describes the reduction in mean foci number and foci size in metastasis-positive mice after T22-GFP-H6-FdU
treatment, as compared to Buffer or free oligo-FdU.
B T22-GFP-H6-FdU induces a higher reduction in CXCR4+ cancer cell fraction (CXCR4+ CCF) in liver, lung, and peritoneal metastatic tissue, at the end of treatment, than
free oligo-FdU, as measured by anti-CXCR4 IHC. In contrast, T22-GFP-H6-FdU or free oligo-FdU does not reduce the CXCR4+ CCF in LN Mets or primary tumor tissue
after therapy (N = 6 mice per Buffer group; N = 7 mice per free oligo-FdU group; and N = 8 mice per T22-GFP-H6-FdU group; 3 samples/mouse). Data expressed as
mean  s.e.m. Comparison of remaining CXCR4+ CCF by site between groups: (B: Buffer; F: free oligo-FdU; T-F: T22-GFP-H6-FdU). P-values for statistical differences:
T-F vs. B: *P = 0.012 for LV Mets, *P = 0.027 for LG Mets; *P = 0.038 for PTN Mets (green lines), T-F vs. F: *P = 0.013 for LV Mets (black line). Mann–Whitney U-test.
C Representative CXCR4 IHC images of the reduction in CXCR4+ CCF induced by T22-GFP-H6-FdU (or its absence in free oligo-FdU mice) at the end of treatment, in the
M5 patient-derived CRC model, which quantitation is reported in panel (B). In the M5 model, the highest reduction in foci number and size occurs in liver metastases,
which show the highest reduction in CXCR4+ CCF. Note the correlation between the reduction in CXCR4+ CCF induced by T22-GFP-H6-FdU and its antimetastatic
effect at each site, measured as number of liver, lung, or peritoneal Mets (Table 1) in the M5 metastatic CRC models [as it happens in the SW1417 model
(Appendix Fig S8)]. Note in both Table 1 and Appendix Table S1 that 83% of mice in the T22-GFP-H6-FdU group remained free of liver, lung, or peritoneal metastases
at the end of treatment in the SW1417 CRC model, whereas in the M5 CRC model these parameters were in the 38–63% range. Scale bar, 100 lm. Asterisks, tumor
tissue; N, normal tissue; LN, lymphatic metastasis.
▸Figure 7. Negligible T22-GFP-H6-FdU biodistribution or toxicity on non-tumor tissues.A Undetectable T22-GFP-H6-FdU emitted fluorescence in normal tissues, except for a transient accumulation 5 h after a 100 lg dose in the liver, which disappears at
24 h. Liver emitted fluorescence is transient and significantly lower than the one registered in tumor tissue. Tumor/Liver ratio = 7.5 (see tumor intensity in Fig 2B,
which was registered in the same experiment; N = 5 mice/group). Scale bar, 1 cm. Color key, radiant efficiency units.
B Representative images depicting the level of DNA double-strand break (DSB) induction in histologically normal bone marrow 5 h after treatment, as measured by
anti-c-H2AX, which is higher in free oligo-FdU-treated mice than in T22-GFP-H6-FdU (P = 0.047). Low level of cells containing DSBs in histologically normal kidney
after T22-GFP-H6-FdU or free oligo-FdU treatment, a finding occurring in all normal tissues analyzed (N = 50, 5 mice/group; 10 fields/mouse). Scale bar, 100 lm.
C Representative images showing lack of histopathological alterations in H&E-stained tissue or apoptotic induction in H&E-stained samples of CXCR4+ (bone marrow)
and CXCR4 (brain, kidney, liver, lung, and heart) normal tissues 24 h after the administration of a 100 lg dose of T22-GFP-H6-FdU or an equimolecular dose of free
oligo-FdU (N = 5/group). Note that the transient nanoconjugate distribution to liver or the DNA damage induced in bone marrow does not lead to cytotoxicity on
these non-tumor tissues (N = 50, 5 mice/group; 10 fields/mouse). Scale bar, 100 lm.
D Lack of differences in body weight among groups registered along time in the SW1417-derived CCR model and the regression of metastases protocol (mean  s.e.m.,
N = 10 mice/group).
E Lack of differences in body mouse weight among groups registered along time in the SW1417 cell line-derived model and the prevention of metastasis protocol
[mean  s.e.m., Buffer (N = 11; free oligo-FdU (N = 12), T22-GFP-H6-FdU (N = 12)].
F Lack of differences in body mouse weight among groups registered along time in the M5 patient-derived model and the prevention of metastasis protocol
[mean  s.e.m., Buffer (N = 6); free oligo-FdU (N = 17); T22-GFP-H6-FdU (N = 8)].
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2012). As expected, this nanoconjugate shows also low potency at
controlling primary tumor growth, which relates to self-renewal
rather than to cell trafficking (Steeg, 2016; Brabletz et al, 2005;
Sleeman & Steeg, 2010; Oskarsson et al, 2014). This is also in
agreement with CRC CD133+CXCR4+ CRC cells displaying CSC
and MetSC capacities, whereas CD133+ CXCR4 cells have only
CSC capacity (Zhang et al, 2012), which further supports the
notion that T22-GFP-H6-FdU selectively targets the subset of
CXCR4+ MetSCs rather than CSCs.
Our nanoconjugate displayed also a high therapeutic window,
since we achieved selective CXCR4+ tumor cell uptake and high
antimetastatic effect while achieving negligible distribution (as
reported for T22-GFP-H6; Ce´spedes et al, 2016) or histological alter-
ations in normal tissues (expressing or not CXCR4) with no sign of
toxicity or body weight lost. This is consistent with the very high
level of CXCR4 expression in poor prognosis CRC (Kim et al, 2005,
2006; Schimanski et al, 2005) and other neoplasias (Fischer et al,
2008; Nimmagadda et al, 2009; van den Berg et al, 2011) in compar-
ison with non-tumor tissues.
In summary, we demonstrated that targeted drug delivery to
metastatic stem cells (MetSCs) aimed at their selective depletion is
a clinically relevant and reachable therapeutic goal for metastasis
control in CRC, with no associated toxicity, when using
protein-based nanoconjugates such as T22-GFP-H6-FdU. To our
knowledge, this is the first compound that achieves selective anti-
metastatic effect, which supports a change in drug development
focus from primary tumor to metastasis control (Steeg & Theodor-
escu, 2008; Weber, 2013; Steeg, 2016) that is expected to highly
enhance its clinical impact, considering that metastases continue
causing most cancer deaths (Mehlen & Puisieux, 2006; Spano et al,
2012; Riihima¨ki et al, 2016). Our results support its use mostly in
the neoadjuvant setting to achieve early-stage metastasis control in
non-metastatic high-risk patients or in patients with limited
disease as proposed (Steeg, 2012, 2016; Weber, 2013). We also
expect to increase therapeutic precision in the use of the nanocon-
jugate by selecting candidate patients with high CXCR4 overex-
pression, who are likely to respond, and determining CXCR4+ CCF
along time to monitor their response to treatment. A similar thera-
peutic approach could be implemented for metastasis control in a
variety of cancer types in which CXCR4+ MetSCs associate with
poor prognosis (Balkwill, 2004; Kucia et al, 2005; Hermann et al,
2007).
Materials and Methods
Synthesis of the T22-GFP-H6-FdU therapeutic nanoconjugate
T22-GFP-H6 is a protein nanoparticle produced in bacteria using a
recombinant DNA strategy, as previously described (Unzueta et al,
2012a). The nanoconjugate was synthesized by covalent binding of
the targeting vector and oligo-FdU, a pentameric oligonucleotide
of Floxuridine (5-Fluoro-20-deoxyuridine; Sigma-Aldrich Chemie
GmbH, Steinheim, Germany), both functionalized before their
conjugation. The oligo-FdU was functionalized with a thiol group as
described in Appendix Fig S1, and T22-GFP-H6 was functionalized
by reacting with the linker 4-maleimido hexanoic acid N-hydroxy-
succinimide ester (Thermo Fisher, Waltham, MA, USA), following
the protocol for biofunctionalization of proteins described by
Hermanson (2013). This linker binds the amino groups of the exter-
nal lysines of the T22-GFP-H6 protein adding maleimido groups.
The final T22-GFP-H6-FdU nanoconjugate was obtained reacting
T22-GFP-H6 functionalized with maleimide and oligo-FdU-thiol
(Michael reaction; Nair et al, 2014). The final reaction product was
purified by dialysis, as previously described for T22-GFP-H6
(Unzueta et al, 2012b). The functionalization and physico-chemical
characterization of oligo-FdU with thiol are described in
Appendix Fig S1. The physico-chemical and functional characteriza-
tion of the reaction products for the synthesis of T22-GFP-H6-FdU is
described in Appendix Fig S2.
CXCR4 and SDF-1a expression in SW1417 cells
CXCR4+ luciferase+ SW1417 CRC cells expressing the luciferase
reporter gene (derived from the parental SW1417 human colorectal
cell line, ATCC CCL238TM, Manassas, VA, USA) were cultured in
modified Eagle’s medium (Gibco, Thermo Fisher, Waltham, MA,
USA) supplemented with 10% fetal calf serum (Gibco) and incu-
bated at 37°C and 5% CO2 in a humidified atmosphere.
Fluorescence-activated cell sorting (FACS) analysis was
performed in duplicate to verify cell surface expression of CXCR4.
Briefly, one million CXCR4+ luciferase+ SW1417 cells were washed
in phosphate-buffered saline containing 0.5% bovine serum albu-
min (PBS–BSA) and incubated for 30 min at 4°C with PE-Cy5 mouse
anti-human CXCR4 monoclonal antibody or PE-Cy5 mouse IgG2a as
an isotype control (BD Biosciences, Becton Dickinson, Franklin
Lakes, NY, USA). Unbound antibody was removed by two washes
with PBS–BSA. Data acquisition was performed using flow cytome-
try (FACSCalibur, Becton Dickinson, Franklin Lakes, NY, USA) and
analyzed by Cell Quest Pro software.
To quantify SDF-1a release, 5 × 104 CXCR4+ luciferase+
SW1417 or 1BR3.G fibroblasts (SDF-1a-expressing cells used as
control; ECACC, Cat. No. 90020507, Salisbury, UK cells) were
cultured in DMEM with 10% FBS on a 24-well plate, for 48 or 72 h.
Media was recovered at these times to measure their level of SDF-1a
using a commercially SDF-1a ELISA kit (RayBiotech, Norcross, GA,
USA). Experiments were performed in duplicate.
T22-GFP-H6-FdU internalization, CXCR4 specificity, and
cytotoxicity in CXCR4+ cells in vitro
We assessed the internalization capacity of the nanoconjugate by
exposing CXCR4+ luciferase+ SW1417 cells for 1 h to 1 lM T22-
GFP-H6-FdU concentration, treating them with 1 mg/ml trypsin
(Gibco, Waltham, MA, USA) for 15 min, and measuring the green
emitted fluorescence of the internalized nanoconjugate particles in
the FACSCanto system cytometer (Becton Dickinson, Franklin
Lakes, NJ, USA), using a 15 mW air-cooled argon ion laser at
488 nm excitation. Fluorescence emission was measured with a D
detector (530/30-nm band-pass filter).
To assess specificity for CXCR4 receptor-mediated internaliza-
tion, we performed competition studies incubating CRC SW1417
cells with the CXCR4 antagonist AMD3100 (Sigma-Aldrich, Saint
Louis, MO, USA) in a 1:10 (protein:antagonist) molar ratio for 1 h
before exposure to the nanoconjugate at 1 lM for an additional
hour.
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T22-GFP-H6-FdU subcellular localization was performed by cultur-
ing the cells in MatTek culture dishes (MatTek Co., Ashland, MA,
USA); then, T22-GFP-H6-FdU was added in OptiPro medium supple-
mented with L-glutamine. The nuclei were labeled with 0.2 lg/ml
Hoechst 33342 (Molecular Probes, Eugene, OR, USA) and the plasma
membranes with 2.5 lg/ml CellMaskTM Deep Red (Molecular
Probes, Eugene, OR, USA) for 10 min in the dark and washed in
phosphate-buffered saline (Sigma-Aldrich). Live cells were recorded
by TCS-SP5 confocal laser scanning microscopy (Leica Microsystems,
Wetzlar, Germany) using a Plan Apo 63×/1.4 (oil HC × PL APO
lambda blue) objective. To determine particle localization inside the
cell, stacks of 10–20 sections for every 0.5 lm of cell thickness were
collected and three-dimensional models were generated using Imaris
version 7.2.1 software (Bitplane, Zurich, Switzerland).
Next, we studied T22-GFP-H6-FdU cytotoxic activity measuring cell
viability and using the MTT metabolic test (Roche, Basel, Switzer-
land), following manufacturer recommendations. To that purpose, we
exposed SW1417 CRC cells to T22-GFP-H6-FdU at 1.0–1,000 nM
concentration range and measured their viability at 72 h as compared
to equimolecular concentrations of T22-GFP-H6 or free oligo-FdU. We
then construct a dose–response curve and determine the linearized
T22-GFP-H6-FdU dose–response trend line for each compound.
Generation of CCR mouse models
Experiments were approved by the Mouse Ethics Committee at
Hospital de la Santa Creu i Sant Pau.
We used three different CRC mouse models, one generated by
subcutaneous CRC cell implantation to study nanoconjugate biodis-
tribution and induction of CRC apoptosis, and two generated by
orthotopic cell implantation to study the antimetastatic effect, either
for prevention of metastases or regression of established metastases.
To generate two of these models, we used 5-week-old Swiss nude
mice, whereas in one model we used NOD-SCID mice. They were all
female mice weighing 18–20 g (Charles River, L’Arbresle, France)
and were housed in a sterile environment with bedding, water, and
c-ray-sterilized food ad libitum.
Subcutaneous (SC) mouse CRC model
We generated a subcutaneous CRC model injecting 1 × 107 CXCR4+
luciferase+ SW1417 human CRC cells (expressing luciferase to allow
bioluminescence monitoring of tumor growth) re-suspended in
250 ll of media in the mouse flank. When tumors reached 700 mm3
were excised and implanted SC tumor aliquots (3 × 3 × 3 mm) by
the trocher system in a cohort of mice. SC model was used to assess
tumor uptake, nanoconjugate internalization, and in vivo competition
studies by co-administration of the CXCR4 antagonist AMD3100. It
was also used to determine the induction of DNA double-strand
breaks, tumor cell apoptosis, and the fraction of CXCR4+ cancer cells
remaining in tumor tissue (CXCR4+ CCF) along time after treatment,
as described below. These data were used to design the required
dosage interval for the nanoconjugate repeated dose therapy in subse-
quent experiments aimed to determine its antimetastatic effect.
Orthotopic (ORT) CRC mouse model used to study regression of
established metastases
Swiss nude mice were anesthetized with ketamine and xylazine,
exteriorizing their cecum by a laparotomy. 2 × 106 CXCR4+
luciferase+ SW1417 CRC cells (expressing luciferase, to allow
ex vivo bioluminescent identification of metastatic foci in affected
organs) were suspended in 50 ll of modified Eagle’s medium and
loaded into a sterile micropipette. We slowly injected the cell
suspension, under a binocular lens, with an approximate 30° angle,
and its tip introduced 5 mm into the cecal wall (intracecal microin-
jection) as described (Ce´spedes et al, 2007). We sealed the entry
injection point using BioGlue Surgical Adhesive (CryoLife Inc,
Kennesaw, GA, USA) to avoid the reflux of implanted cells and to
ensure that no seeding in the peritoneal wall occurred during the
procedure. This model was used to evaluate the capacity of the T22-
GFP-H6-FdU nanoconjugate to induce the regression of established
metastases.
Orthotopic (ORT) CRC mouse model to study prevention of metastases
We generated an efficient metastatic model in NOD/SCID mice that
received an intracecal microinjection (ORT) of CXCR4+ luciferase+
SW1417 CRC cells disaggregated from SC tumors previously gener-
ated in a different cohort of NOD/SCID mice. We also generated a
highly efficient metastatic model in NSG mice that received an
intracecal microinjection of M5 patient-derived CRC tumor cells
disaggregated from SC tumors previously generated in a different
cohort of NSG mice (SC + ORT models) as previously described
(Alamo et al, 2014; Rueda et al, 2015). Briefly, when SC tumors
reached a volume of 700 mm3, mice were sacrificed by cervical
dislocation and tumors were excised, discarding the necrotic areas,
and 300 mg of viable tumor tissue was then cut into pieces and
disaggregated in a mix of 0.05% trypsin (Invitrogen) and 100 mg/
ml DNase (Sigma-Aldrich). The mix was pipetted 30 times, using a
10-ml pipette, and incubated for 10 min at 37°C with shaking. It
was then re-pipetted 30 times, using 10-, 3-, and 1- pipettes, and re-
incubated for 5 min at 37°C with shaking. The obtained SW1417
single-cell or M5 patient-derived cell suspensions were filtered
through a cell strainer and centrifuged at 1,000 g for 10 min before
counting the cells. We then microinjected 2 × 106 cells, previously
grown in culture and re-suspended in 50 ll of media, in the cecum
of each mouse. These models were used to evaluate the capacity
of the T22-GFP-H6-FdU nanoconjugate to prevent metastasis
development.
Evaluation of Spheroid formation capacity
To evaluate spheroid formation capacity after treatment, mice bear-
ing SW1417 CXCR4+ luciferase+ or M5 patient-derived tumors were
treated with 100 lg of T22-GFP-H6-FdU, the equimolar dose of free
oligo-Fdu or vehicle for two consecutive days (N = 2 mouse/group).
At 24 h post-treatment, tumors were excised and mechanically and
enzymatically disaggregated with a mixture of collagenase IV
(0.5 mg/ml) and DNAsa (0.1 mg/ml) in DMEM media at 37°C
(Alamo et al, 2014). Isolated cells were cultured at 106 cells for 48 h
in cancer stem cell media consisting in DMEM/F12, N2 supplement
1×, Hepes 1 M, L-glutamine, glucose 45% (Invitrogen, Carlsbad, CA,
USA) Trace elements B and C (1/1,000×; VWR, Barcelona, Spain),
2 lg/ml heparine, 10 lg/ml insulin (Sigma-Aldrich), 0.02 lg/ml
human EGF, 0.01 lg/ml human, and b-FGF (Peprotech, London,
UK) and using T25 ultralow attachment surface coating flasks
(Gibco) in order to minimize cell adherence. We measured spheroid
formation by counting the number of spheroids generated from
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isolated and cultured cells derived from treated tumors under a
contrast phase microscope (200× of magnification) (N = 8; 2 mice/
group; 4 plates/mice).
Evaluation of tumor re-initiation capacity
To assess tumor formation capacity after treatment, we inoculated 5
million cells per flank (right and left) in NSG mice that were
obtained from the disaggregated M5 tumors generated in these mice
after being treated with 100 lg T22-GFP-H6-FdU or the equimolar
dose of FdU for two consecutive days (n = 4 tumors/group). We
registered tumor burden at the point injection site every 2 days and
tumor volume using a caliper, measuring the two perpendicular
diameters [short diameter (S) and large diameter (L)] of each tumor
and applying the following formula: Tumor volume = L*S2/2.
T22-GFP-H6-FdU tumor uptake, tumor cell internalization, and
induction of DNA damage and apoptosis in vivo
We used the SC CXCR4+ SW1417 CRC model to assess the internal-
ization of the T22-GFP-H6-FdU nanoconjugate into the cytosol of
CXCR4+ tumor cells after the administration of 100 lg T22-GFP-H6-
FdU as an i.v. single bolus compared with Buffer, T22-GFP-H6 (un-
targeted nanoconjugate), and oligo-FdU (unconjugated free drug).
Two, 5, and 24 h after the administration, we euthanized the mouse,
resected the tumor, and registered ex vivo the intensity of the green
fluorescence emitted by the nanoconjugate that had biodistributed to
tumor tissue, using the IVIS 200-Spectrum (PerkinElmer, Waltham,
MA, USA). Following, we took tumor tissue samples and performed
immunofluorescence (IF) and immunohistochemistry (IHC) to assess
the presence or absence of the corresponding nanoconjugate in the
membrane and/or cytosol of tumor cells using an anti-GFP antibody
(1:300; Santa-Cruz Biotechnology, CA, USA). We also assess
nanoconjugate CXCR4-dependence for internalization, as previously
described for the T22-GFP-H6 nanoparticle in (Unzueta et al, 2012a).
The presence and localization of T22-GFP-H6-FdU nanoconjugate
(detecting its GFP domain) were assessed by immunofluorescence
labeling of formalin-fixed paraffin-embedded (FFPE) samples using
standard protocols. Primary antibodies anti-CXCR4 (1:300, Abcam,
Cambridge, UK) and anti-GFP (1:250, Abcam, UK) were incubated
ON at 4°C. Then, we used the secondary antibodies: chicken IgG-
Cy2 for GFP and rabbit IgG-Cy3 for CXCR4. Slides were then stained
with DAPI (1:10,000 in TBS) for 10 min RT, rinsed with water,
mounted, and analyzed under fluorescence microscope (405 nm,
488 Cy2 and 532/561 filters). Representative pictures were taken
using confocal Leica TCS SPE at 200× or 600× magnifications.
Immunofluorescence measurements were performed using the
ImageJ software. Data were expressed as mean area  s.e.m (lm2)
(N = 5 mice/group).
Once, we determined the specific internalization of T22-GFP-H6-
FdU in CXCR4+ cancer cells in tumor tissue, we assessed if this
nanoconjugate also induced genotoxic damage and apoptosis in
tumor tissue, before studying if both activities lead to CXCR4+
cancer cell elimination. To that purpose, we treated the SC SW1417
mouse model, with a single 100 lg iv dose of T22-GFP-H6-FdU, or
equimolar doses of T22-GFP-H6, free oligo-FdU, or Buffer. Five
hours later, we sacrificed the mice and counted the number of cells
containing double-strand breaks (DSBs) in tumor tissue, as assessed
by IHC using an anti-c-H2AX mAb (1:400, Novus Biologicals,
Cambridge, UK) as previously described (Kuo & Yang, 2008; Geng
et al, 2010; Podhorecka et al, 2010). To that purpose, we counted
the number of cells containing nuclei that stained positive for DSBs,
using anti-c-H2AX mAb IHC, in ten 400× magnification fields in one
tumor section per mouse (N = 5 mice/group).
We also compared the capacity of T22-GFP-H6-FdU for apoptosis
induction after the administration of an equimolecular dose of, T22-
GF-H6, free oligo-FdU, or Buffer. Apoptotic signaling was assessed
5 h after treatment, by evaluation of cells positive for active cleaved
caspase-3 as measured by IHC, whereas apoptotic induction was
assessed 24 h after treatment, by counting the number of condensed
or defragmented nuclei, after Hoechst staining. Both parameters
were measured in ten 400× high-power magnification fields, in dif-
ferent sections from each tumor, using the Olympus DP73 digital
camera.
Definition of the optimal dose interval by changes in CXCR4+
tumor cell number after T22-GFP-H6-FdU administration
We also used the SC SW1417 mouse model, to determine the
capacity of the nanoconjugate to induced DNA damage and apopto-
sis in tumor tissue, and its relationship with the kinetics of CXCR4
expression levels in the membrane of tumor cells after treatment,
regarding the fraction of CXCR4 expressing tumor cells and their
intensity, since CXCR4+ are the target cells for the nanoconjugate.
To that purpose 24, 48, and 72 h after the administration of a
single i.v. bolus of 100 lg T22-GFP-H6-FdU, we euthanize the
mice, took tumor samples, fix, and paraffin-embedded them to
determine the levels and the percent of tumor cells expressing
CXCR4 using IHC with an anti-CXCR4 antibody (1:300, Abcam,
UK) as previously described (Ce´spedes et al, 2014). We used mice
treated with equimolecular dosages of T22-GFP-H6, free oligo-FdU,
or Buffer, in which we also determined the levels of CXCR4 expres-
sion in tumor tissue at the different times points. The results of the
kinetics of CXCR4 expression in tumor cells were used to establish
the optimal T22-GFP-H6-FdU nanoconjugate administration interval
in the repeated dose schedule used to evaluate antimetastatic
effect.
Evaluation of tumor emboli intravasation capacity in early
metastatic experiment
We used the M5 patient-derived CRC model in NSG mice to evaluate
the capacity of the nanoconjugate to block tumor emboli intravasa-
tion. NSG mice received an intracecal microinjection of M5 patient-
derived CRC tumor cells (2 × 106) disaggregated from SC tumors as
described in the above section. At day 7 post-inoculation, mice were
treated with i.v. bolus of 100 lg T22-GFP-H6-FdU or the equimolar
dose of free oligo-FdU or Buffer for two consecutive days and eutha-
nized 24 h later (N = 5/group). The primary tumor was collected,
fix, and paraffin-embedded for histopathology evaluation. Intrava-
sated tumor emboli were determined by microscopic analysis under
200× magnification in H&E-stained primary tumor sections. We
counted the vascular (blood or lymphatic) invasion by identifying
tumor emboli that were invading an endothelium-lined vessel-like
structure within the submucosa of the colonic wall, where a major-
ity of vasa are located, and recording their number. Identification of
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tumor emboli was done in H&E-stained tumor sections, under 200×
magnification in each section, in five different mice per group.
CXCR4 expression per tumor emboli was evaluated by using anti-
CXCR4 IHC and calculating H-score (multiplying percent of CXCR4+
cells out of total cell number in the emboli area by their staining
intensity), scoring each from 0 to 3 (where three is the maximal
intensity) per tumor emboli area (N = 5 mice/group) using Cell^D
Olympus software (v3.3.).
Treatment protocol for the evaluation of T22-GFP-H6-FdU
induction of metastasis regression
We used the orthotopic and metastatic CRC model developed in
Swiss nude mice to perform experiment of metastasis regression.
We randomized 40 mice in a non-blinded manner into four
groups: Buffer, T22-GFP-H6, T22-GFP-H6-FdU, and free oligo-FdU
(n = 10/group) and administered repeated i.v. boluses at
equimolecular doses, as follows: T22-GFP-H6-FdU: 20 lg, free
oligo-FdU: 2.6 nmols, or Buffer, every 3 days (q3d) for a total of
10 doses. We initiated the T22-GFP-H6-FdU administration
2 months after tumor cell implantation, the time at which we
determined, in previous experiments, that lymph node and lung
metastases were present (see Appendix Fig S4). The experiment
was finished when the first animal of the Buffer-treated group
required to be euthanized. See below the studied parameters to
evaluate the antimetastatic effect.
Treatment protocol for the evaluation of T22-GFP-H6-FdU
metastasis prevention effect
We used the SC + ORT metastatic SW1417 CRC model developed in
NOD/SCID or the M5 patient-derived CRC model in NSG mice to
evaluate the capacity of the nanoconjugate for metastasis preven-
tion. In each experiment, we non-blinded randomized mice into
three groups: Buffer (n = 7–11), T22-GFP-H6-FdU (n = 8–12), and
free oligo-FdU (n = 7–8) and administered repeated i.v. boluses at
equimolecular doses, as follows: T22-GFP-H6-FdU: 20 lg; free oligo-
FdU: 2.6 nmols; or Buffer), every 3 days (q3d) for a total of 12
doses in the SW1417 model or seven doses in M5 model. We initi-
ated the T22-GFP-H6-FdU administration 1 week after tumor cell
implantation before metastatic dissemination has occurred (see
Appendix Fig S4). The experiment was finished when the first
animal of the Buffer-treated-group required to be euthanized.
Evaluation of antimetastatic effect and determination
of the CXCR4+ cancer cell fraction in tumor tissue at the end
of treatment
At the end of both, the regression and the prevention of metastasis,
experiments, we applied the same methodology to determine T22-
GFP-H6-FdU antimetastatic effect. At necropsy, we recorded the
number and size of visible metastasis in the organs where dissemi-
nation is expected in colorectal cancer (lymph nodes, liver, lung,
and peritoneum) for each mouse in all compared groups. In the
luciferase+ SW1417-derived CRC model, we also counted ex vivo
the number of metastatic foci that emitted bioluminescence in
the target organs for metastasis, using the IVIS 200-Spectrum
(PerkinElmer).
We collected and processed samples for histopathological and
immunohistochemical analyses. Two independent observers
analyzed H&E-stained samples to count the number and measure
the size of all observed metastatic foci in sections of each organ in
each mouse. We used an Olympus microscope with the Cell^D
Olympus software (v3.3) to take images and perform the measure-
ments.
We determine CXCR4 expression in tumor tissue, using IHC with
an anti-CXCR4 antibody, as described above, to determine the frac-
tion of CXCR4+ cancer cells remaining in tumor tissue (CXCR4+
CCF) after treatment, including primary tumor and metastatic foci at
the different organs affected by metastases (peritoneum, liver, lung,
and lymph nodes). The obtained results were used to study a possi-
ble correlation between CXCR4+ CCF and antimetastatic effect at
the different sites.
T22-GFP-H6-FdU biodistribution and toxicity in normal organs
We assessed T22-GFP-H6-FdU uptake measuring the green fluores-
cence emitted by the GFP domain of the nanoconjugate, as well as
DNA DSBs and apoptotic induction in normal (non-tumor) tissues
using the methodology described above. In addition, two indepen-
dent observers evaluated the possible histopathological alterations
observed in H&E-stained non-tumor tissue samples, searching for
signs of toxicity. These tissues included CXCR4-expressing organs
(despite expressing this receptor to a significantly lower level than
in tumor tissue) where the nanoconjugate could accumulate such as
the bone marrow and spleen and we also evaluated the toxicity in
non-CXCR4 expressing organs, especially those in which the uncon-
jugated oligo-FdU such as the liver.
Statistical analysis
Sample size was defined on the basis of previous preliminary experi-
ments. Neither animals nor samples were excluded from the analy-
ses. Randomization of animals into control and experimental groups
was performed using the SPSS program. Histology and immunohis-
tochemical samples were coded so that the researcher that analyzed
them did not know to which group they belong to. Normal distri-
bution of the data was tested using the Shapiro–Wilk test. The
homogeneity of the variance between groups was tested using the
Levene’s test. We used the Fisher’s exact test to analyze possible
differences between control and experimental groups of affected
mice regarding metastatic rates at the different organs. The non-
parametric tests, Kruskal–Wallis, and post hoc pairwise Mann–
Whitney U two-sided tests were used to compare number and size
of metastatic foci in the affected organs among groups. All quanti-
tative values were expressed as mean  s.e.m. All statistical tests
were performed using SPSS version 11.0 (IBM, New York, NY,
USA). Differences among groups were considered significant at a
P < 0.05.
Expanded View for this article is available online.
Acknowledgements
This work was supported by Plan Estatal de I+D+I 2013-2016, Instituto de
Salud Carlos III and MINECO (co-funding from FEDER, Integrated Project of
Excellence PIE15/00028, PI18/00650, PI15/00378, PI15/00272, PI12/00327, PI17/
ª 2018 The Authors EMBO Molecular Medicine e8772 | 2018 19 of 22
María Virtudes Céspedes et al MetSCs killing as antimetastatic therapy EMBO Molecular Medicine
Published online: September 6, 2018 
00150, BIO2013-41019-P CTQ2014-52588-R, and BFU2010-17450), AGAUR
(2017 SGR 865, 2017 SGR 229, 2014PROD-00055), MaratóTV3 (416/C/2013), La
Caixa Foundation, and CIBER-BBN Nanomets and Nanoprother Intramural
Projects, and used CIBER-BBN Nanotoxicology and Protein Production Plat-
forms for its development. GOA and NBT groups are part of the Spanish ICTS-
141007 NANBIOSIS Network for Nanomedicine. M.V.C and U.U. are supported
by Miguel Servet and Sara Borrell contracts from ISCIII, respectively. P.A.
obtained a Fellowship from the Josep Carreras Research Institute. A.V. received
an ICREA ACADEMIA Award.
Author contributions
Conception and design: RM, AV, EV, MVC, and UU. Development of
methodology: MVC, UU, AA, RE, AS-C, PA, RS, AG, IC, and MAM. Acquisition
of data: MVC, UU, AA, EV, RS, PA, AG, and AS-C. Analysis and interpretation
of data: RM, AV, RE, EV, MVC, UU, AA, IC, and AL-P. Writing of the manu-
script: RM, AV, EV, RE, and MVC. Review and/or revision of the manuscript:
UU, RE, IC, MAM, AS-C, PA, AG, RS, AA, and AL-P. Study supervision: RM,
AV, and EV.
Conflict of interest
EV, UU, AV, MVC, IC, and RM are co-inventors of a patent (WO2012095527)
covering the use of T22 as an intracellular targeting agent.
References
Alamo P, Gallardo A, Pavón MA, Casanova I, Trias M, Mangues MA, Vázquez
E, Villaverde A, Mangues R, Céspedes MV (2014) Subcutaneous
preconditioning increases invasion and metastatic dissemination in mouse
colorectal cancer models. Dis Model Mech 7: 387 – 396
Balkwill F (2004) The significance of cancer cell expression of the chemokine
receptor CXCR4. Semin Cancer Biol 14: 171 – 179
van den Berg NS, Buckle T, Kuil J, Wesseling J, van Leeuwen FW (2011)
Immunohistochemical detection of the CXCR4 expression in tumor tissue
using the fluorescent peptide antagonist Ac-TZ14011-FITC. Transl Oncol 4:
234 – 240
Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T (2005) Migrating cancer
stem cells-an integrated concept of malignant tumour progression. Nat
Rev Cancer 5: 744 – 749
Céspedes MV, Espina C, García-Cabezas MA, Trias M, Boluda A, Gómez del
Pulgar MT, Sancho FJ, Nistal M, Lacal JC, Mangues R (2007) Orthotopic
microinjection of human colon cancer cells in nude mice induces tumor
foci in all clinically relevant metastatic sites. Am J Pathol 170:
1077 – 1085
Céspedes MV, Unzueta U, Tatkiewicz W, Sánchez-Chardi A, Conchillo-Solé O,
Álamo P, Xu Z, Casanova I, Corchero JL, Pesarrodona M et al (2014) In vivo
architectonic stability of fully de novo designed protein-only nanoparticles.
ACS Nano 8: 4166 – 4176
Céspedes MV, Unzueta U, Álamo P, Gallardo A, Sala R, Casanova S, Pavón MA,
Mangues MA, Trías M, López-Pousa A et al (2016) Cancer-specific uptake
of a liganded protein nanocarrier targeting aggressive CXCR4+ colorectal
cancer models. Nanomedicine 12: 1987 – 1996
Chen F, Zhuang X, Lin L, Yu P, Wang Y, Shi Y, Hu G, Sun Y (2015) New
horizons in tumor microenvironment biology: challenges and
opportunities. BMC Med 13: 45
Croker AK, Allan AL (2008) Cancer stem cells: implications for the progression
and treatment of metastatic disease. J Cell Mol Med 12: 374 – 390
Das M, Mohanty C, Sahoo SK (2009) Ligand-based targeted therapy for
cancer tissue. Expert Opin Drug Deliv 6: 285 – 304
Fischer T, Nagel F, Jacobs S, Stumm R, Schulz S (2008) Reassessment of
CXCR4 chemokine receptor expression in human normal and neoplastic
tissues using the novel rabbit monoclonal antibody UMB-2. PLoS One 3:
e4069
Gassmann P, Haier J, Schlüter K, Domikowsky B, Wendel C, Wiesner U, Kubitza
R, Engers R, Schneider SW, Homey B et al (2009) CXCR4 regulates the early
extravasation of metastatic tumor cells in vivo. Neoplasia 11: 651 – 661
Geng L, Huehls AM, Wagner JM, Huntoon CJ, Karnitz LM (2010) Checkpoint
signaling, base excision repair, and PARP promote survival of colon cancer
cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil. PLoS One 6:
e28862
Goswami S, Wang W, Arakawa T, Ohtake S (2013) Developments and
challenges for mAb-based therapeutics. Antibodies 2: 452 – 500
The paper explained
Problem
In colorectal cancer (CRC), adjuvant therapy controls tumor progres-
sion and prolongs survival at the expense of high toxicity; however,
metastases remain the primary cause of death. There is an urgent
need to develop less toxic and more effective antimetastatic agents.
CXCR4 receptor-overexpressing (CXCR4+) cells are metastatic stem
cells (MetSCs) since they initiate metastases. Moreover, high CXCR4
tumor expression associates with metastatic dissemination and
confers poor patient prognosis, a finding similar to other cancers. We
hypothesized that a protein-based nanoconjugate (T22-GFP-H6-FdU)
that selectively delivers the genotoxic drug Floxuridine (FdU) to
CXCR4+ MetSCs will be antimetastatic.
Results
In contrast to free oligo-FdU, intravenous administration of T22-GFP-
H6-FdU selectively accumulates and internalizes in CXCR4+ cancer
cells, triggering DNA damage and apoptosis, which leads to the selec-
tive depletion of CXCR4+ MetSCs and to reduced tumor formation and
spheroid formation. As compared to free oligo-FdU, repeated T22-GFP-
H6-FdU administration, in cell line and patient-derived CRC mouse
models, blocks CXCR4+ tumor emboli intravasation in colonic peri-
tumoral vessels and completely prevents metastases development in a
high percent of mice. In addition, this nanoconjugate induces CXCR4
expression-dependent and site-dependent reduction in foci number
and size in liver, peritoneal, or lung metastases in the rest of mice.
T22-GFP-H6-FdU induces also higher regression of established metas-
tases than free oligo-FdU, with negligible biodistribution or toxicity in
normal tissues, showing, therefore, a high therapeutic index.
Impact
The observation of a potent antimetastatic effect validates metastatic
stem cells (MetSCs) as targets for clinical therapy. Moreover, to our
knowledge, this protein-based nanoconjugate is the first compound
that achieves a selective antimetastatic effect, which supports a
change in drug development focus from primary tumor to metastasis
control. This new approach is expected to highly enhance its clinical
impact in CRC and other cancer types in which CXCR4 mediates
metastasis development. Our results support the use of this nanome-
dicine in the neoadjuvant setting to achieve early-stage metastasis
control in non-metastatic high-risk patients or in patients with
limited disease as proposed. Its use could also increase therapeutic
precision by selecting candidate patients with high CXCR4 overexpres-
sion, who are likely to be sensitive to the nanoconjugate, and deter-
mining CXCR4+ cancer cell fraction along time to monitor their
response.
20 of 22 EMBO Molecular Medicine e8772 | 2018 ª 2018 The Authors
EMBO Molecular Medicine MetSCs killing as antimetastatic therapy María Virtudes Céspedes et al
Published online: September 6, 2018 
Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ,
Heeschen C (2007) Distinct populations of cancer stem cells determine
tumor growth and metastatic activity in human pancreatic cancer. Cell
Stem Cell 1: 313 – 323
Hermanson G (2013) Bioconjugate techniques, 3rd edn, pp 1200 . London:
Academic Press
Hernandez L, Magalhaes MA, Coniglio SJ, Condeelis JS, Segall JE (2011)
Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis. Breast
Cancer Res 13: R128
Jin F, Brockmeier U, Otterbach F, Metzen E (2012a) New insight into the SDF-
1/CXCR4 axis in a breast carcinoma model: hypoxia-induced endothelial
SDF-1 and tumor cell CXCR4 are required for tumor cell intravasation. Mol
Cancer Res 10: 1021 – 1031
Jin K, Gao W, Lu Y, Lan H, Teng L, Cao F (2012b) Mechanisms
regulating colorectal cancer cell metastasis into liver. Oncol Lett 3:
11 – 15
Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, Foshag L, Bilchik AJ,
Hoon DS (2005) Chemokine receptor CXCR4 expression in colorectal
cancer patients increases the risk for recurrence and for poor survival. J
Clin Oncol 23: 2744 – 2753
Kim J, Mori T, Chen SL, Amersi FF, Martinez SR, Kuo C, Turner RR, Ye X,
Bilchik AJ, Morton DL et al (2006) Chemokine receptor CXCR4
expression in patients with melanoma and colorectal cancer liver
metastases and the association with disease outcome. Ann Surg 244:
113 – 120
Kreso A, van Galen P, Pedley NM, Lima-Fernandes E, Frelin C, Davis T,
Cao L, Baiazitov R, Du W, Sydorenko N et al (2014) Self-renewal as
a therapeutic target in human colorectal cancer. Nat Med 20:
29 – 35
Kucia M, Reca R, Miekus K, Wanzeck J, Wojakowski W, Janowska-Wieczorek A,
Ratajczak J, Ratajczak MZ (2005) Trafficking of normal stem cells and
metastasis of cancer stem cells involve similar mechanisms: pivotal role of
the SDF-1-CXCR4 axis. Stem Cells 23: 879 – 894
Kuo LJ, Yang LX (2008) Gamma-H2AX. A novel biomarker for DNA double-
strand breaks. In Vivo 22: 305 – 309
Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of
action and clinical strategies. Nat Rev Cancer 5: 330 – 338
Mehlen P, Puisieux A (2006) Metastasis: a question of life or death. Nat Rev
Cancer 6: 449 – 458
Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan
T, Murphy E, Yuan W, Wagner SN et al (2001) Involvement of
chemokine receptors in breast cancer metastasis. Nature 410:
50 – 56
Murakami T, Kawada K, Iwamoto M, Akagami M, Hida K, Nakanishi Y,
Kanda K, Kawada M, Seno H, Taketo MM et al (2013) The role of
CXCR3 and CXCR4 in colorectal cancer metastasis. Int J Cancer 132:
276 – 287
Nair DP, Podgorski M, Chatani S, Gong T, Xi W, Fenoli CR, Bowman CN (2014)
The Thiol-Michael addition click reaction: a powerful and widely used tool
in materials chemistry. Chem Mater 26: 724 – 744
Nimmagadda S, Pullambhatla M, Pomper MG (2009) Immunoimaging of
CXCR4 expression in brain tumor xenografts using SPECT/CT. J Nucl Med
50: 1124 – 1130
Oskarsson T, Batlle E, Massagué J (2014) Metastatic stem cells: sources,
niches, and vital pathways. Cell Stem Cell 14: 306 – 321
Podhorecka M, Skladanowski A, Bozko P (2010) H2AX phosphorylation: its role
in DNA damage response and cancer therapy. J Nucleic Acids 2010:
920161
Rhodes DR, Chinnaiyan AM (2005) Integrative analysis of the cancer
transcriptome. Nat Genet 37(Suppl): S31 – S37
Riihimäki M, Hemminki A, Sundquist J, Hemminki K (2016) Patterns of
metastasis in colon and rectal cancer. Sci Rep 6: 29765
Rueda F, Céspedes MV, Conchillo-Solé O, Sánchez-Chardi A, Seras-Franzoso J,
Cubarsi R, Gallardo A, Pesarrodona M, Ferrer-Miralles N, Daura X et al
(2015) Bottom-up instructive quality control in the biofabrication of smart
protein materials. Adv Mater 27: 7816 – 7822
Schimanski CC, Schwald S, Simiantonaki N, Jayasinghe C, Gönner U,
Wilsberg V, Junginger T, Berger MR, Galle PR, Moehler M (2005)
Effect of chemokine receptors CXCR4 and CCR7 on the metastatic
behavior of human colorectal cancer. Clin Cancer Res 11:
1743 – 1750
Schimanski CC, Bahre R, Gockel I, Müller A, Frerichs K, Hörner V, Teufel A,
Simiantonaki N, Biesterfeld S, Wehler T et al (2006) Dissemination of
hepatocellular carcinoma is mediated via chemokine receptor CXCR4. Br J
Cancer 95: 210 – 217
Schrag D (2004) The price tag on progress–chemotherapy for colorectal
cancer. N Engl J Med 351: 317 – 319
Shi L, Zhao J, Lu Q, Chen X, Wang H, Jiang Y, Wu J, Ji M, Xu B, Chen L et al
(2015) Initial hepatic artery infusion and systemic chemotherapy for
asymptomatic colorectal cancer with un-resectable liver metastasis. Int J
Clin Exp Med 8: 1000 – 1008
Sleeman J, Steeg PS (2010) Cancer metastasis as a therapeutic target. Eur J
Cancer 46: 1177 – 1180
Spano D, Heck C, De Antonellis P, Christofori G, Zollo M (2012) Molecular
networks that regulate cancer metastasis. Semin Cancer Biol 22: 234 – 249
Steeg PS, Theodorescu D (2008) Metastasis: a therapeutic target for cancer.
Nat Clin Pract Oncol 5: 206 – 219
Steeg PS (2012) The right trials. Nature 485: S58 – S59
Steeg PS (2016) Targeting metastasis. Nat Rev Cancer 4: 201 – 218
Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ,
Wang J (2010) CXCL12/CXCR4/CXCR7 chemokine axis. Cancer Metastasis
Rev 29: 709 – 722
Takebayashi K, Mekata E, Sonoda H, Shimizu T, Shiomi H, Naka S,
Endo Y, Tani T (2013) Differences in chemosensitivity between
primary and metastatic tumors in colorectal cancer. PLoS One 8:
e73215
Unzueta U, Ferrer-Miralles N, Cedano J, Zikung X, Pesarrodona M,
Saccardo P, García-Fruitós E, Domingo-Espín J, Kumar P, Gupta KCet al
(2012a) Non-amyloidogenic peptide tags for the regulatable
self-assembling of protein-only nanoparticles. Biomaterials 33:
8714 – 8722
Unzueta U, Céspedes MV, Ferrer-Miralles N, Casanova I, Cedano J, Corchero
JL, Domingo-Espín J, Villaverde A, Mangues R, Vázquez E (2012b)
Intracellular CXCR4+ cell targeting with T22-empowered protein-only
nanoparticles. Int J Nanomedicine 7: 4533 – 4554
Unzueta U, Céspedes MV, Vázquez E, Ferrer-Miralles N, Mangues R, Villaverde
A (2015) Towards protein-based viral mimetics for cancer therapies. Trends
Biotechnol 33: 253 – 258
Vignot S, Lefebvre C, Frampton GM, Meurice G, Yelensky R, Palmer G, Capron
F, Lazar V, Hannoun L, Miller VA et al (2015) Comparative analysis of
primary tumour and matched metastases in colorectal cancer patients:
evaluation of concordance between genomic and transcriptional profiles.
Eur J Cancer 51: 791 – 799
Wang TB, Hu BG, Liu DW, Shi HP, Dong WG (2014) The influence of
lentivirus-mediated CXCR4 RNA interference on hepatic metastasis of
colorectal cancer. Int J Oncol 44: 1861 – 1869
ª 2018 The Authors EMBO Molecular Medicine e8772 | 2018 21 of 22
María Virtudes Céspedes et al MetSCs killing as antimetastatic therapy EMBO Molecular Medicine
Published online: September 6, 2018 
Weber GF (2013) Why does cancer therapy lack effective anti-metastasis
drugs? Cancer Lett 2: 207 – 211
Wendel C, Hemping-Bovenkerk A, Krasnyanska J, Mees ST, Kochetkova M,
Stoeppeler S, Haier J (2012) CXCR4/CXCL12 participate in extravasation of
metastasizing breast cancer cells within the liver in a rat model. PLoS One
7: e30046
Zeelenberg IS, Ruuls-Van Stalle L, Roos E (2003) The chemokine receptor
CXCR4 is required for outgrowth of colon carcinoma micrometastases.
Cancer Res 63: 3833 – 3839
Zhang SS, Han ZP, Jing YY, Tao SF, Li TJ, Wang H, Wang Y, Li R, Yang Y, Zhao
X et al (2012) CD133(+)CXCR4(+) colon cancer cells exhibit metastatic
potential and predict poor prognosis of patients. BMC Med 10: 8
License: This is an open access article under the
terms of the Creative Commons Attribution 4.0
License, which permits use, distribution and reproduc-
tion in any medium, provided the original work is
properly cited.
22 of 22 EMBO Molecular Medicine e8772 | 2018 ª 2018 The Authors
EMBO Molecular Medicine MetSCs killing as antimetastatic therapy María Virtudes Céspedes et al
Published online: September 6, 2018 
